Press release – Medexprim enters the US market, will present its solutions at RSNA, Chicago

Medexprim, the European leading provider of enriched imaging and clinical datasets for research projects, announces its expansion into the US market.

2021 marks the return to the in person-event edition of the Radiological Society of North America (RSNA) meeting in Chicago, from November 28 to December 2. Medexprim will be very pleased to welcome their imaging clients, partners, and soon-to-be partners.

Medexprim seizes this opportunity to consolidate its network of leading data partners hospitals and oncology centers in the USA, thanks to its US partner Illuminate. The Chicago event will lead to a new meeting with the National Cancer Institute and the National Institutes of Health.

Romain Cazavan, CEO of Medexprim, says: “Our approach and tools have significantly matured since our last participation in RSNA in 2019. We now participate in ambitious European projects, such as CHAIMELON and build multicentric Data Lakes by disease. Our ability to aggregate imaging data and associated clinical data allows our data partners to go even further in leveraging data, both in their clinical research projects but also to optimize routine care. We are very happy to meet hospitals, physicians, clients and partners. It is a tremendous opportunity to share our innovative solutions and services at the time we enter the US market.”

Medexprim’s booth is #4851 (South Hall Level 3)
__________________
About Medexprim
MEDEXPRIM I Real-World Evidence for better Care
Medexprim is the European leader in reliable extraction of imaging and clinical data to accelerate clinical research. As a specialist of Real-World Data, we build bridges between leading university hospitals and pharmaceutical, AI and Medical device companies. In compliance with GDPR/HIPAA, we help hospitals stimulate their own clinical research strategy and leverage their data, thanks to our software and services designed with and for physicians. We provide our partners with secure access to high-quality regulatory-grade data. Medexprim aims to build multi-centric data lakes by disease to serve oncology, neurology and cardiology. We help to solve the equation “one patient, one disease, one treatment” to develop personalized medicine for better care.
www.medexprim.com – LinkedIn: linkedin.com/company/medexprim

Press contact: Anne-Sophie Labeta
Email: aslabeta@medexprim.com